TBCA

TBCA is a highly selective CK2 (casein kinase II) inhibitor with an IC50 of 110 nM and a Ki of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases[1][2].

Research Areas >> Cancer

Signaling Pathways >> Cell Cycle/DNA Damage >> Casein Kinase

Signaling Pathways >> Stem Cell/Wnt >> Casein Kinase

CK2:110 nM (IC50)

CK2:77 nM (Ki)

TBCA (0-100 μM; 24 hours) shows a drastic effect on Jurkat cells viability[1]. TBCA also inhibits CK2 double mutant (Val66 Ile174) with an IC50 of 0.68 μM[1]. TBCA dose-dependently inhibits platelet aggregation and secretion induced by various agonists including 2-MeSADP, AYPGKF, SFLLRN, and CRP. TBCA also inhibits phosphorylation of PDK1, Akt, and GSK3β induced by AYPGKF[2]. Cell Viability Assay[1] Cell Line: Jurkat cells Concentration: 0-100 μM Incubation Time: 24 hours Result: The viability of Jurkat cells was reduced.

[1]. Pagano MA, et al. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem. 2007;8(1):129-139.

[2]. Ryu SY, Kim S. Evaluation of CK2 inhibitor (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid (TBCA) in regulation of platelet function. Eur J Pharmacol. 2013;720(1-3):391-400.